PolyPid (PYPD, Financial) is gearing up for significant milestones in 2025. The company remains optimistic about the SHIELD II Phase 3 trial, now considered less risky. This confidence is bolstered by a reassessment involving 800 patients, which aims to ensure adequate statistical power to validate the effectiveness of D-PLEX100, potentially increasing the trial's success chances.
As PolyPid anticipates the release of top-line results for SHIELD II later this quarter, it is making strides in preparing for NDA and MAA submissions expected in 2026. Meanwhile, the company continues to formulate its commercial strategies and is actively engaging in partnership discussions with multiple prospective partners within the United States.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for PolyPid Ltd (PYPD, Financial) is $11.33 with a high estimate of $13.00 and a low estimate of $10.00. The average target implies an upside of 318.20% from the current price of $2.71. More detailed estimate data can be found on the PolyPid Ltd (PYPD) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, PolyPid Ltd's (PYPD, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
